Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Leukemia, Myeloid, Acute 5Pathologic Complete Response 2Myelodysplastic Syndromes 2Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Small Cell Lung Carcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasms 1Multiple Myeloma 1Leukemia 1Colorectal Neoplasms 1

Interventions

Paclitaxel 2tislelizumab 1stenoparib 1sargramostim 1pembrolizumab 1margetuximab 1bintrafusp alfa protein, human 1Temozolomide 1Standard of Care 1Specimen Handling 1Practice Guidelines as Topic 1Paracentesis 1Palliative Care 1N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide 1Monatide (IMS 3015) 1Magnetic Resonance Spectroscopy 1Granulocyte-Macrophage Colony-Stimulating Factor 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Monatide (IMS 3015) × Other hematologic neoplasm × Clear all
NCT03761914 2024-11-19

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Sellas Life Sciences Group

Phase 1/2 Completed
26 enrolled 14 charts
BreastGastrointestinalGynecologicOther hematologic neoplasmThoracic

Ovarian Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡